MedTrace Logo

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

NCT05930119 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-09-06

No results posted yet for this study

Summary

A Phase 1, Open-label, 4-Period, Randomized 6-Sequence Study to Evaluate the Effect of Food and Rabeprazole, a Proton Pump Inhibitor, on the Pharmacokinetics of HMPL-453 in Healthy Volunteers

Conditions

  • Intrahepatic Cholangiocarcinoma

Interventions

DRUG

HMPL-453

300 mg HMPL-453

DRUG

Rabeprazole

20 mg of rabeprazole will be administered by mouth once daily.

Sponsors & Collaborators

  • Hutchmed

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-17
Primary Completion
2023-08-28
Completion
2023-08-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05930119 on ClinicalTrials.gov